24 November 2008 - Synthon announces that it has successfully completed multiple decentralized procedures (DCP) for its latest product Pramipexole. Regulatory clearance has been obtained for Synthon's product in thirteen European countries. Synthon' s product is a generic version of the anti-Parkinson agent Pramipexole.
The details can be read here.
No comments:
Post a Comment